Two hits are better than one: synergistic anticancer activity of α-helical peptides and doxorubicin/epirubicin

Jing Zhao; Yibing Huang; Dong Liu; Yuxin Chen

doi:10.18632/oncotarget.2754

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Two hits are better than one: synergistic anticancer activity of α-helical peptides and doxorubicin/epirubicin

Jing Zhao _, Yibing Huang, Dong Liu and Yuxin Chen

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:1769-1778. https://doi.org/10.18632/oncotarget.2754

Metrics: PDF 2107 views | HTML 2797 views | ?

Abstract

Jing Zhao1,3, Yibing Huang1,2,3, Dong Liu1,3, Yuxin Chen1,2,3

1Key Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, Jilin University, Changchun, China

2National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, China

3School of Life Sciences, Jilin University, Changchun, China

Correspondence to:

Yuxin Chen, e-mail: [email protected]

Keywords: Anticancer peptides, doxorubicin/epirubicin, synergy, mechanism of action, xenograft model

Received: September 17, 2014 Accepted: November 15, 2014 Published: December 19, 2014

ABSTRACT

This study explored combinational anticancer therapy using α-helical peptides HPRP-A1/HPRP-A2 with the chemical drugs doxorubicin (DOX) and epirubicin (EPI). The in vitro activity of these drugs against different cancer cell lines was synergistically increased, as was their activity in a HeLa xenograft model in BALB/c nude mice. We delineated the mechanism of this synergy by studying the apoptosis pathway and morphologic changes in the HeLa cell membrane. The mechanism of the HPRP-A1/DOX combination was found to involve enhanced apoptosis, which seemed to be caspase-dependent and involved both the extrinsic and intrinsic parts of the caspase cascade in HeLa cells. Combined application of HPRP-A1 and DOX at low concentrations was significantly more effective than either drug alone against HeLa tumors in the mouse xenograft model. This type of combination therapy appears to have great clinical potential.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2754

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Two hits are better than one: synergistic anticancer activity of α-helical peptides and doxorubicin/epirubicin

Abstract